C12-200
CAS No. 1220890-25-4
C12-200( —— )
Catalog No. M28191 CAS No. 1220890-25-4
C12-200 is a benchmark ionizable cationic lipidoid along with helper lipids. C12-200 is commonly used for mRNA delivery.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 176 | Get Quote |
|
| 10MG | 282 | Get Quote |
|
| 25MG | 480 | Get Quote |
|
| 50MG | 691 | Get Quote |
|
| 100MG | 972 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameC12-200
-
NoteResearch use only, not for human use.
-
Brief DescriptionC12-200 is a benchmark ionizable cationic lipidoid along with helper lipids. C12-200 is commonly used for mRNA delivery.
-
DescriptionC12-200 is a benchmark ionizable cationic lipidoid along with helper lipids. C12-200 is commonly used for mRNA delivery.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorCB2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1220890-25-4
-
Formula Weight1136.93
-
Molecular FormulaC70H145N5O5
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (87.96 mM)
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Lipopolysaccharides,...
Lipopolysaccharides, Escherichiacoli (E. coli O111:B4) are derived from Escherichia coli O111:B4 and are a unique component of the cell wall of Gram-negative bacteria.
-
HLM006474
HLM006474 is a pan inhibitor of E2F. This inhibits E2F4 DNA-binding (IC50: 29.8 μM in A375 cells).HLM006474 causes the viability of both SCLC and NSCLC lines (IC50 ranging from 15 to 75 μM). HLM006474 displays little activities against E2F4 DNA-binding in A375 cells at 10 and 20 μM, apparently inhibits E2F4 DNA-binding at 40 μM, and increasingly suppresses the effect at 60 and 80 μM concentrations.
-
3-Methyladipic acid
3-Methyladipic acid is a metabolite of the catabolism of phytanic acid. Patients with adult Refsums disease (ARD) are unable to detoxify phytanic acid by alpha-oxidation and so the w-oxidation pathway is the only metabolic pathway available for phytanic acid degradation.
Cart
sales@molnova.com